1
At CPHI Frankfurt, we sat down with Alex Del Priore, head of large molecule and interim head of small molecule at Syngene International, to discuss the company’s recent investments in peptides and antibody–drug conjugates (ADCs) and the broader evolution of integrated development in biologics.
1) Syngene has recently invested in peptide synthesis and a new bioconjugation suite for antibody–drug conjugates. What is driving this expansion in your large molecule portfolio?
The industry is moving toward more complex biologics. We see strong pipelines in ADCs, peptides,…